|
Groups
| | |
A
|
B
|
C
|
D
|
|---|
|
Virus tested
| | |
B-gD&gCS
|
Bartha K61
|
/
|
/
|
|
Dosage
| | |
1 × 106 TCID50
|
PBS
|
/
|
|
Inoculation route
| | |
Intramuscularly
| |
|
ELISA antibodies against PRV gB or gE
|
B.V.
|
gB+
|
0a/5b
|
0/5
|
0/5
|
0/5
|
|
gE+
|
0/5
|
0/5
|
0/5
|
0/5
|
|
7d P.V.
|
gB+
|
5/5
|
5/5
|
0/5
|
0/5
|
|
gE+
|
0/5
|
0/5
|
0/5
|
0/5
|
|
14 d P.C.
|
gB+
|
5/5
|
5/5
|
2/5
|
0/5
|
|
gE+
|
5/5
|
5/5
|
2/5
|
0/5
|
|
Clinical signs P.V.
| |
0/5
|
0/5
|
0/5
|
0/5
|
|
Fever frequency (≥40.5 °C) P.V.
| |
0/5
|
0/5
|
0/5
|
0/5
|
|
Virus shedding P.V.
| |
0/5
|
0/5
|
/
|
/
|
|
Fever frequency (≥40.5 °C) P.C.
| |
0/5
|
0/5
|
5/5
|
0/5
|
|
Clinical signs P.C.
|
Morbidity
|
0/5
|
0/5
|
5/5
|
0/5
|
|
Duration (days)
|
/
|
/
|
4~12
|
/
|
|
Mortality
|
0/5
|
0/5
|
3/5
|
0/5
|
|
Virus shedding P.C.
|
Frequency
|
3/5
|
5/5
|
5/5
|
0/5
|
|
Titer (TCID50/g)
|
102.49~106.19
|
101.30~109.82
|
101.30~108.83
|
/
|
|
Duration (days)
|
1~8
|
4~10
|
3~10
|
/
|
|
Lung lesions P.C.
| |
0/5
|
0/5
|
5/5
|
0/5
|
- B.V. before vaccination, P.V. post vaccination, P.C. post challenge, gB+ antibodies against PRV gB positive, gE+ antibodies against PRV gE positive, “/”, not applicable; athe number of piglets positive; bthe number of piglets in the group
